Insulet Corporation (PODD) shares plunged 5.11% in Thursday's intraday trading, despite the company reporting better-than-expected third-quarter results and raising its full-year revenue growth guidance. The medical device maker, known for its wearable insulin pumps, posted strong quarterly performance but failed to impress investors amid broader market concerns.

For the third quarter ended September 30, Insulet reported adjusted earnings of $1.24 per share, surpassing analysts' expectations of $1.14 per share. Revenue jumped 29.9% year-over-year to $706.3 million, beating the consensus estimate of $676.73 million. The company's flagship Omnipod product line drove growth, with total Omnipod revenue reaching $699.2 million, up 31% from the previous year.

Despite the robust results, Insulet's stock took a hit in the market. The sell-off appears to be driven by several factors, including concerns about valuation in the broader healthcare and technology sectors, as well as potential market saturation for insulin pumps. Additionally, some investors may have been expecting even stronger guidance or were disappointed by the lack of significant upside surprises in the report.

Insulet raised its full-year 2025 revenue growth forecast to 28-29%, up from its previous projection of 24-27%. The company also increased its annual Omnipod revenue growth guidance to 29-30%, compared to the earlier forecast of 25-28%. While these revisions are positive, they may not have been enough to justify the stock's recent gains or alleviate concerns about future growth rates in a competitive market.

The market's reaction to Insulet's earnings highlights the current volatility in high-growth healthcare stocks and underscores the challenges companies face in meeting increasingly high investor expectations, even when delivering strong financial results.